Zhongmin Maxwell Wang
A5036211366- Cancer Immunotherapy and Biomarkers
- Endometrial and Cervical Cancer Treatments
- Cancer Mechanisms and Therapy
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- Lung Cancer Research Studies
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Erythrocyte Function and Pathophysiology
- Nanoparticle-Based Drug Delivery
- Brain Metastases and Treatment
- Colorectal and Anal Carcinomas
- Histone Deacetylase Inhibitors Research
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Adenosine and Purinergic Signaling
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
Shanghai Jiao Tong University
2024
Ruijin Hospital
2024
Public Procurement Service
2022
Clinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application this has been limited by toxicities. Cadonilimab (AK104) is a symmetric tetravalent bispecific with crystallizable fragment (Fc)-null design. In addition to demonstrating biological activity similar the CTLA-4 antibodies, cadonilimab possess higher...
Importance For patients with non–small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. Objective To compare the efficacy of ivonescimab plus chemotherapy alone for relapsed advanced or metastatic epidermal growth factor receptor ( ) variant. Design, Setting, and Participants Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China...
Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, bispecific antibody targeting PD-1 CTLA-4, plus standard therapy first-line R/M CC (recurrent and/or metastatic cancer).
Simultaneous inhibition of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) with bispecific antibodies may improve efficacy over single-agent treatment while limiting toxicity. Cadonilimab is a humanized, antibody targeting PD-1 CTLA-4. This phase 1 study cadonilimab including dose escalation (n = 39) expansion 80). One dose-limiting toxicity event observed, the maximum tolerated not reached. 6 mg/kg once every 2 weeks established as recommended...
Purpose This multicenter, open-label, phase Ib/II study aimed to assess the efficacy and safety of cadonilimab, a humanized, tetravalent, bispecific antibody plus lenvatinib in first-line treatment advanced hepatocellular carcinoma (aHCC). Methods Patients with histologically confirmed aHCC were included receive either 6 mg/kg cadonilimab every 2 weeks (cohort A) or 15 3 B). The primary endpoint was objective response rate (ORR) by RECIST v1.1, while secondary endpoints safety,...
Background Studies showed that vascular endothelial growth factor (VEGF) inhibitors could improve therapeutic efficacy of PD-1/PD-L1 antibodies by transforming the immunosuppressive tumor microenvironment (TME) into an immunoresponsive TME. Ivonescimab is a first-in-class, humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously. Here, we report first-in-human, phase 1a study ivonescimab in patients with advanced solid tumors. Methods Patients tumors were treated...
CD47 is a widely expressed transmembrane glycoprotein that delivers an antiphagocytic signal on macrophages through its interaction with SIRPα. highly in cancer cells and overexpression correlated poor prognosis. blocking antibodies are actively being developed worldwide for therapy, the most challenging concern associated hematotoxicity. Ligufalimab (AK117) novel humanized IgG4 anti-CD47 antibody without hemagglutination effect. Blockade of CD47-SIRPα pathway by AK117 leads to promising...
Abstract Background: Studies have shown that the combination of PD-1 inhibitors with chemotherapy exhibits promising efficacy as a first-line treatment for Asian patients recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). This presentation reports results global phase 3 clinical trial ethnically diverse treated penpulimab plus vs. placebo therapy R/M NPC (NCT04974398). Methods: AK105-304 was conducted across 46 sites worldwide. Participants aged 18-75 years previously...
2630 Background: AK117 is a novel humanized IgG4 monoclonal antibody (mAb) targeting CD47, macrophage immune checkpoint that allows tumor cells to evade destruction by phagocytic cells. CD47 target expressed in many cancers. However, the initial dose of anti-CD47 therapy may be limited severe anemia due ubiquitous expression on senescent red blood (RBCs). Here, we present encouraging preliminary safety and receptor occupancy (RO) data from an ongoing dose-escalation study patients (pts) with...
4031 Background: Anti-PD-1 monoclonal antibodies plus chemo as first-line therapy for advanced G/GEJ cancer yields OS and PFS benefits compared to alone while the survival are limited, especially in patients with low PD-L1 expression (CPS<5). Simultaneous blockade of PD-1 CTLA-4 pathways has shown synergistic anti-tumor activity been proven effective across multiple types. This phase Ib/Ⅱ dose-escalation study evaluated safety efficacy AK104, a PD-1/CTLA-4 bispecific antibody, combined...
7529 Background: Penpulimab is a humanized IgG1 monoclonal antibody (mAb) that blocks PD-1 binding to PD-L1. Penpulimab, with its unique epitope, was engineered eliminate Fc-mediated effector function compromises anti-tumor immune cell function, and optimize receptor occupancy by improving duration of drug binding. functions, such as ADCC/ADCP, have been observed in most IgG4 anti-PD-1 mAbs but absent penpulimab, thereby potentially reducing the occurrence immune-related adverse reactions....
2515 Background: AK112 is a tetrameric bispecific antibody targeting PD-1 and VEGF-A. Published data suggests that the combination of anti-VEGF-A with immune checkpoint inhibitor (ICI) therapy produces complementary synergistic antitumor effects. Given strong correlation between VEGF-A expression in tumor microenvironment, it postulated simultaneous blockade these 2 targets by as single agent might achieve higher target binding specificity produce enhanced activity, an improved safety...
Abstract Penpulimab is an anti-programmed cell death-1 (PD-1) IgG1 antibody with no Fc gamma receptor (FcγR) binding activity, and thus theoretically reduced immune-related adverse events (irAEs) while maintaining efficacy. This single-arm, phase II trial conducted across 20 tertiary care centers in China enrolled adult patients metastatic nasopharyngeal carcinoma (NPC) who had failed two or more lines of previous systemic chemotherapy. Patients received 200-mg penpulimab intravenously every...
TPS2675 Background: AK119 is a humanized IgG1 monoclonal antibody (mAb) that selectively binds to and inhibits the ectonucleotidase activity of CD73, cell surface enzyme converts adenosine monophosphate (AMP) into adenosine. Adenosine has been shown facilitate tumor-mediated evasion. CD73 inhibition may therefore reduce accumulation promote anti-tumor immunity. AK104 recombinant bispecific simultaneously programmed death protein 1 (PD-1) cytotoxic T- lymphocyte-associated antigen 4 (CTLA-4)....
<p>Supplementary Figure S2. Kaplan-Meier Curve of Progression Free Survival (PFS).</p>